Showing 891-900 of 1784 results for "".
Spotlight on Asia-Pacific: Practice Beyond Borders
https://reachmd.com/programs/cme/spotlight-on-asia-pacific-practice-beyond-borders/39810/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Routes Reconsidered: A Case-Based Debate in SERD Selection
https://reachmd.com/programs/cme/routes-reconsidered-a-case-based-debate-in-serd-selection/39807/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Unmet Needs in Endocrine Therapy: Rethinking the HR+/HER2- mBC Treatment Roadmap
https://reachmd.com/programs/cme/unmet-needs-in-endocrine-therapy-rethinking-the-hrher2-mbc-treatment-roadmap/39797/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Spotlight on Europe: Adapting the Evidence
https://reachmd.com/programs/cme/spotlight-on-europe-adapting-the-evidence/39808/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Breaking Down the Benchmarks: Pivotal Data on First-Line CDK4/6 Inhibitors
https://reachmd.com/programs/cme/breaking-down-the-benchmarks-pivotal-data-on-first-line-cdk46-inhibitors/39798/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Doublet or Triplet? A Case-Based Debate in First-Line Choices for HR+/HER2- mBC
https://reachmd.com/programs/cme/doublet-or-triplet-a-case-based-debate-in-first-line-choices-for-hrher2-mbc/39806/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Safety of CDK4/6 Inhibitors: Anticipation, Prevention, and Management of Adverse Events
https://reachmd.com/programs/cme/safety-of-cdk46-inhibitors-anticipation-prevention-and-management-of-adverse-events/39799/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.The Digital Doctor: Hope, Hype, & Harm at the Dawn of Medicine's Computer Age
https://reachmd.com/programs/book-club/digital-doctor-hope-hype-and-harm-dawn-medicines-computer-age/8364/Dr. Maurice Pickard talks with Dr. Robert Wachter about the role of technology in changing medical care.Vedolizumab as Induction and Maintenance Therapy for Crohn’s Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy
https://reachmd.com/programs/Audioabstracts/vedolizumab-induction-and-maintenance-therapy-crohns-disease-patients-naive-or-who-have-failed-tumor/9537/Vedolizumab had increased efficacy over placebo in CD patients irrespective of TNF-α antagonist treatment history.Multiple Eruptive Myxoid Dermatofibromas in Patient With History of HIV
https://reachmd.com/programs/practical-dermatology/multiple-eruptive-myxoid-dermatofibromas-in-patient-with-history-of-hiv/24216/Multiple eruptive dermatofibromas, a rare presentation of dermatofibroma, has been associated with altered immunity such as HIV/AIDS.